相关实验视频
Updated: May 16, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.5K
评估基于持续血糖监测的胰岛素定位协议,用于非重症监护病房的2型糖尿病患者
Mikkel Thor Olsen1,2, Ulrik Pedersen-Bjergaard2,3, Signe Hjejle Jensen2
1Steno Diabetes Center Copenhagen, Herlev-Gentofte Hospital, Copenhagen University Hospital, Hilleroed, Denmark.
Journal of diabetes science and technology
|April 5, 2025
概括
在非重症监护病房成功实施了基于持续血糖监测 (CGM) 的胰岛素定位方案. 该协议显示了高度的遵守和可用性,为住院糖尿病患者管理提供了一个框架.
科学领域:
- 内分泌学 在内分泌学.
- 糖尿病管理 糖尿病管理
- 医疗信息学 医疗信息学
背景情况:
- 缺乏基于持续血糖监测 (CGM) 的标准化胰岛素定位协议,阻碍了住院患者的血糖控制.
- 这项研究评估了Olsen等人. 在非重症监护室 (非ICU) 设置中对2型糖尿病患者的协议的可接受性和可操作性.
研究的目的:
- 评估基于CGM的特定胰岛素定位方案的可行性和接受性,用于在重症监护室以外的住院2型糖尿病患者.
- 在住院糖尿病患者团队中确定协议的遵守率和可用性.
主要方法:
- 一个住院糖尿病团队的七名成员在353天内为84名患者管理了胰岛素调整.
- 团队可以遵循或取代基底,食和校正胰岛素的基于CGM的协议,并通过问卷评估可用性.
主要成果:
- 观察到高坚持协议:96.3%的基础胰岛素,和83.9%-92.6%的午餐胰岛素跨餐.
- 所有的校正胰岛素定位都遵循了协议. 团队成员对协议可用性进行了高度评价 (平均分数为7.4-8.7/10).
结论:
- 基于CGM的胰岛素定位方案由奥尔森等人撰写. 在非ICU环境中对2型糖尿病住院患者有效实施.
- 该协议在医疗保健团队中表现出高度接受和可用性,为住院患者的CGM整合提供了可行的框架.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
129
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
129
Diabetes: Management and Pharmacotherapy
214
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
214
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Insulin Formulations: Types and Delivery
143
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
143
Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
Hypoglycemia and Glucagon
143
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
143

